ALLUVI: A IN-DEPTH INVESTIGATION INTO THE MEDICATION'S POTENTIAL

Alluvi, known as BI 4744, presents a significant breakthrough in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates remarkable efficacy in clinical assessments, possibly exceeding existing GLP-1 targ